BioNTech SE - ADR vs iShares International Treasury Bond ETF — how do they compare? BioNTech SE - ADR trades at $93.06 (market cap $23.31B), while iShares International Treasury Bond ETF trades at $41.23. Which is the better fit depends on your goals.
| BNTX | IGOV | |
|---|---|---|
Market Cap | $23.31B | — |
Sector | Health | — |
52-Week High | $119.34 | $43.09 |
52-Week Low | $83.89 | $40.35 |
Enterprise Value | $6.60B | — |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
IGOV, an iShares International Treasury Bond ETF, trades at $41.21, showing minimal daily movement with a 0.05% gain. The technical outlook is bullish based on moving averages, while oscillators are neutral. Recent news highlights significant downside risk due to its high duration exposure amid global inflationary pressures and geopolitical tensions, which could lead to capital losses as benchmark rates rise.
The outlook for IGOV is clouded by macroeconomic headwinds; rising global interest rates pose a substantial risk to its bond holdings. Investment opportunity exists for those seeking international treasury exposure, but caution is warranted due to sensitivity to rate changes and ongoing energy-related market volatility.
Trailing returns across standard periods
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →